OTCMKTS:NVZMF Novozymes A/S (NVZMF) Stock Price, News & Analysis $66.03 -0.89 (-1.34%) As of 09/23/2026 01:49 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Novozymes A/S Stock (OTCMKTS:NVZMF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novozymes A/S alerts:Sign Up Key Stats Today's Range$66.03▼$66.0350-Day Range$61.10▼$71.1252-Week Range$52.10▼$72.98Volume150 shsAverage Volume1,464 shsMarket CapitalizationN/AP/E Ratio8.23Dividend Yield2.73%Price TargetN/AConsensus RatingN/A Company Overview Novozymes A/S was a Danish biotechnology company specializing in enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource consumption and develop more sustainable products. The company supplied biological solutions for industries including food and beverages, agriculture, household care, bioenergy, textiles and other manufacturing activities. Its offerings included enzymes used in baking, brewing, animal feed, detergents, biofuels and industrial processing, as well as microbial products intended to support agricultural productivity and environmental performance. Novozymes was established in 2000 after being separated from Novo Nordisk and served customers internationally through research, development and commercial operations across multiple regions. In 2024, Novozymes combined with Chr. Hansen Holding A/S, creating Novonesis, a biosolutions company focused on enzymes, microorganisms and related biological technologies. Novozymes A/S is therefore primarily a historical company name associated with the business now operating under the Novonesis name.AI Generated. May Contain Errors. Read More Novozymes A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreNVZMF MarketRank™: Novozymes A/S scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Novozymes A/S. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Novozymes A/S is 8.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Novozymes A/S is 8.23, which means that it is trading at a less expensive P/E ratio than the Materials sector average P/E ratio of about 26.09.Read more about Novozymes A/S's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverNovozymes A/S has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.Change versus previous monthShort interest in Novozymes A/S has recently decreased by 20.07%, indicating that investor sentiment is improving significantly. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldNovozymes A/S has a dividend yield of 0.72%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthNovozymes A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novozymes A/S is 22.44%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Novozymes A/S's dividend. News and Social Media3.0 / 5News SentimentN/A News SentimentNovozymes A/S has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Materials companies.News Coverage This WeekMarketBeat has tracked 1 news article for Novozymes A/S this week, compared to 0 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novozymes A/S insiders have not sold or bought any company stock.Percentage Held by Institutions20.41% of the stock of Novozymes A/S is held by institutions.Read more about Novozymes A/S's insider trading history. Receive NVZMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVZMF Stock News HeadlinesNovozymes A/S (OTCMKTS:NVZMF) Shares Pass Above Fifty Day Moving Average - Time to Sell?September 19, 2026 | americanbankingnews.comNovonesis (Novozymes) B Class B NVZMFJuly 3, 2026 | morningstar.comMA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Novonesis (Novozymes A/S): Interim report Q1 2026May 5, 2026 | finanznachrichten.deNovonesis (Novozymes A/S): Novonesis expands global footprint with acquisition of production facility in Southeast AsiaApril 8, 2026 | finanznachrichten.deNovozymes (CPSE:NSIS B): Assessing Valuation After Upward Sales Growth Guidance and Improved Q3 ResultsNovember 12, 2025 | finance.yahoo.comCould Gut Microbiome Research Shift Novozymes' Innovation Narrative in Health and Nutrition (CPSE:NSIS B)?September 8, 2025 | finance.yahoo.comNovonesis A/S (NVZMF) Q2 2025 Earnings Call TranscriptAugust 21, 2025 | seekingalpha.comSee More Headlines NVZMF Stock Analysis - Frequently Asked Questions How have NVZMF shares performed this year? Novozymes A/S's stock was trading at $62.4690 on January 1st, 2026. Since then, NVZMF shares have increased by 5.7% and is now trading at $66.03. How were Novozymes A/S's earnings last quarter? Novozymes A/S (OTCMKTS:NVZMF) posted its quarterly earnings results on Wednesday, April, 20th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $2.43 by $2.06. How do I buy shares of Novozymes A/S? Shares of NVZMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/20/2016Today9/23/2026Next Earnings (Estimated)11/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMaterials Industry Chemicals Sub-IndustrySpecialty Chemicals Current SymbolOTCMKTS:NVZMF CIK1131345 Webwww.novonesis.com Phone(454) 446-0000FaxN/AEmployees11,641Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio8.23 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:NVZMF) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredAmazon's touch-enabled robot points to AI's next phaseAmazon wants touch-enabled robots to handle 80% of work across roughly 14 billion warehouse items a year. One ...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novozymes A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novozymes A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
